B dot Medical Successfully Develops Compact Scanning Magnet for Proton Cancer Therapy System
To Downsize Systems and Spread High-precision Irradiation Technology
TOKYO, Sept. 9, 2021 -- (Healthcare Sales & Marketing Network) -- B dot Medical Inc. has conducted an energization test of the scanning magnet, which is designed and manufactured at i... Devices, Oncology, Radiology B dot Medical, proton therapy, compact proton cancer therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 9, 2021 Category: Pharmaceuticals Source Type: news
Telix, Kettering to research PSMA radiotracer
Kettering Health and Telix Pharmaceuticals have signed a deal to study Telix'...Read more on AuntMinnie.comRelated Reading:
Lightpoint, Telix ink collaboration agreement
Telix works with Merck on cancer therapies
Telix Japan names COO
Telix, Monrol reach agreement on therapeutic isotope supply
ARTMS, Telix produce PSMA-11 in cyclotron (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 8, 2021 Category: Radiology Source Type: news
Sharpening a Double-Edged Sword: Bispecific CAR-T Cancer Therapies
David Miklos discusses recent advances in bispecific CAR-T therapy development. (Source: The Scientist)
Source: The Scientist - September 7, 2021 Category: Science Tags: Sponsored Webinars Source Type: news
RenovoRx Receives New 510(k) Clearance for its RenovoCath(R) Delivery System Designed for Targeted Treatment of Solid Tumors
510(k) Device May Improve Targeted Delivery of Chemotherapy
LOS ALTOS, Calif., Sept. 7, 2021 -- (Healthcare Sales & Marketing Network) -- RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announc... Devices, Drug Delivery, Oncology, FDA RenovoRx, RenovoCath Delivery System, RenovoGem, RenovoTAMP (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 7, 2021 Category: Pharmaceuticals Source Type: news
CV Safety Study of Cancer Therapy Attracts Attention CV Safety Study of Cancer Therapy Attracts Attention
Although the first global trial to compare the cardiovascular (CV) safety of two therapies for prostate cancer proved inconclusive, it was"a model for interdisciplinary collaboration" says investigator.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 31, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Review Eyes Nail Toxicities Related to Targeted Cancer Therapy Review Eyes Nail Toxicities Related to Targeted Cancer Therapy
The investigators found that paronychia and periungual pyogenic granulomas were the most common nail unit toxicities caused by targeted therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 24, 2021 Category: Cancer & Oncology Tags: Dermatology News Source Type: news
Lightpoint, Telix ink collaboration agreement
Luminescence imaging technology developer Lightpoint Medical has signed a collaboratio...Read more on AuntMinnie.comRelated Reading:
Telix works with Merck on cancer therapies
Telix Japan names COO
Telix, Monrol reach agreement on therapeutic isotope supply
Lightpoint announces new CEO
Lightpoint gets CE Mark for Sensei device
Lightpoint licenses molecular imaging technology (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 23, 2021 Category: Radiology Source Type: news
Telix works with Merck on cancer therapies
Telix Pharmaceuticals is entering into a collaboration with Merck for researc...Read more on AuntMinnie.comRelated Reading:
Telix Japan names COO
Telix, Monrol reach agreement on therapeutic isotope supply
ARTMS, Telix produce PSMA-11 in cyclotron
Telix files NDA for prostate cancer PET imaging agent
RefleXion, Telix partner on high-risk cancer treatments (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 20, 2021 Category: Radiology Source Type: news
Navrogen raises $3M in venture capital financing to advance cancer therapy platform
The four-year-old company also converted more than $3 million in notes into equity. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 16, 2021 Category: Biotechnology Authors: John George Source Type: news
Researcher Hopes to Improve Tumor Treating Fields for Mesothelioma
Dr. Maurizio D’Incalci already has seen Tumor Treating Fields working for patients with malignant pleural mesothelioma, and applauded the U.S. Food and Drug Administration’s approval of the treatment in 2019.
He also knows the therapy is only scratching the surface of its vast potential and could be even more effective. He wants to help improve it.
D’Incalci, a heralded biomedical science professor at Humanitas University in Milan, Italy, has begun a study exploring various drug combinations that could have a positive, synergistic effect with Tumor Treating Fields for mesothelioma.
“There may be a ...
Source: Asbestos and Mesothelioma News - July 27, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Cancer Therapy and Myocardial Dysfunction: 5 Things to Know Cancer Therapy and Myocardial Dysfunction: 5 Things to Know
An expert overview of some key aspects to preventing, monitoring, and managing cardiac dysfunction related to cancer therapy.American College of Cardiology & Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 26, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Novel imaging agent identifies biomarker for iron-targeted cancer therapies
(Society of Nuclear Medicine and Molecular Imaging) A new radiotracer that detects iron in cancer cells has proven effective, opening the door for the advancement of iron-targeted therapies for cancer patients. The radiotracer, 18F-TRX, can be used to measure iron concentration in tumors, which can help predict whether a not the cancer will respond to treatment. This research was published in the July issue of The Journal of Nuclear Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news
Study on chromosomal rearrangements in yeast reveals potential avenue for cancer therapy
(Osaka University) Researchers from Osaka University have found that the attachment of a ubiquitin molecule to a protein called PCNA at the lysine 107 position causes gross chromosomal rearrangements. This lysine is located where two PCNA molecules interact, and the ubiquitin attachment to it may change the ring structure they form. The ubiquitin attachment occurs through the action of Rad8 (a ubiquitin ligase) and Mms2-Ubc4 (a ubiquitin conjugating enzyme). This implies that inhibiting the human equivalent of this ubiquitination could prevent cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news
Cancer: Information theory to fight resistance to treatments
(Universit é de Gen è ve) A major challenge in cancer therapy is the adaptive response of cancer cells to targeted therapies. Although this adaptive response is theoretically reversible, such a reversal is hampered by numerous molecular mechanisms that allow the cancer cells to adapt to the treatment. A team (UNIGE/HUG) has used information theory, in order to objectify in vivo the molecular regulations at play in the mechanisms of the adaptive response and their modulation by a therapeutic combination. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 21, 2021 Category: International Medicine & Public Health Source Type: news
Scientists provide new insight on how to stop transcription of cancer cells
(University of California - Los Angeles Health Sciences) Findings could help pave the way for cancer therapies that target TAF12, potentially stopping transcription in cancer cells and helping decrease the growth of cancerous tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news
